Section
Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.
Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unrespon
The FDA has approved the first vagus nerve stimulation device for moderate-to-severe rheumatoid arthritis unresponsive to biologic or synthetic DMARDs, offering a novel neuromodulatory approach to disease management.
A 38-year prospective study in Southern Norway demonstrates that isolated polymyalgia rheumatica (PMR) does not increase all-cause mortality compared to matched population controls, with men showing even lower mortality risk.
A phase 3 randomized trial found rituximab no more effective than standard glucocorticoid-based therapy in inducing remission in eosinophilic granulomatosis with polyangiitis (EGPA), with comparable safety and relapse profiles.
Achieving low lupus disease activity (LLDAS) at 12 months is an attainable target in lupus nephritis and independently predicts reduced relapse risk and preserved renal function, supporting its potential as a future treatment goal.
Highlight Rheumatologic diseases—including rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathies, vasculitides, and connective tissue disorders—represent a...
New evidence links direct and indirect exposure to specific agricultural pesticides with increased risk of incident rheumatoid arthritis among female spouses of licensed pesticide applicators.
New WHO guidelines offer evidence-based approaches to improve care for pregnant women with sickle cell disease, focusing on treatment and maternal outcomes.
